2,4 Dinitrophenol (DNP)

2,4-Dinitrophenol (DNP), C₆H₄N₂O₅, is a cellularmetabolic poison. It uncouplesoxidative phosphorylationby carrying protonsacross the mitochondrialmembrane, leading to a rapid consumption of energy without generation of ATP. DNPwas used extensively in the 1930s in diet pills after Cutting and Tainter at Stanford University made their first report on the drug's ability to greatly increase metabolic rate. DNP acts as a protonophore in themitochondrial membrane, uncoupling oxidative phosphorylation and making ATP energy production less efficient. In effect, part of the energy that is normally produced from cellular respiration is wasted as heat. This inefficiency is proportional to the dose of DNP that is taken. Thus, as the dose increases and energy production is made less efficient, the metabolic rate is increased (and more fat is burned) in order to compensate for the inefficiency and meet energy demands. Interestingly, the factor that limits ever increasing doses of DNP is not a lack of ATP energy production, but rather an excessive rise in body temperature due to the heat produced during uncoupling. Accordingly, DNP overdose will cause a fatal fever. Case reports have shown that an acute administration of 20-50 mg/kg in humans can be lethal. Concerns about dangerous side-effects and rapidly developing cataracts resulted in

DNP being discontinued in the United States by the end of 1938. DNP, however, continues to be used by some bodybuilders and athletes to rapidly lose body fat. Fatal overdoses are rare, but are still reported on occasion. These include cases of accidental exposure, suicide, and excessive intentional exposure.

Some advocates of the drug advise people to take doses of 5-8 mg/kg daily. It's commonly advised, however, that the dose be slowly titrated according to personal tolerance, which varies greatly.

There is limited and conflicting data on the pharmacokinetics of DNP in humans. The EPA states that "Data on the elimination kinetics of the dinitrophenolsor their metabolic products in humans were not found." The ATSDR's Toxicological Profile for Dinitrophenols also states that "No studies were located regarding distribution in humans after oral exposure to 2,4-DNP. Limited information is available regarding distribution in animals after oral exposure to 2,4-DNP." However, they do state that "Elimination from the body appears to be rapid, except possibly in cases of compromised liver function." This coincides with a review in the NEJM on the biological actions of dinitrophenol, which stated that "Judging from the metabolic response, DNP appears to be eliminated entirely in three or four days in the presence of liver or kidney damage it is possible that the drug will be retained over a longer period." Oddly, more recent papers give an array of possible half-lives, ranging from 3 hours, to 5-14 days. Other recent papers maintain that the half-life in humans is unknown.

In a study on mice, a lethal dose of 35 mg/kg decreased to 5 mg/kg body weight when the environmental temperature was raised to 39°C (102.2°F). As the ambient temperature increases, so does the risk of overheating. People who use increased ambient temperatures for weight-loss, such as wrestlers and runners, are potentially at greater risk of overdose.

Although further investigation is needed, dinitrophenol-induced hyperthermia has been successfully resolved with dantrolene administration. "Dinitrophenol uncouples oxidative phosphorylation, causes release of calcium from mitochondrial stores and prevents calcium re-uptake. This leads to free intracellular calcium and causes muscle contraction and hyperthermia. Dantrolene inhibits calcium release from the sarcoplasmic reticulum which reduces intracellular calcium. The resulting muscle relaxation allows heat dissipation. There is little risk to dantrolene administration. Since dantrolene may be effective in reducing hyperthermia caused by agents that inhibit oxidative phosphorylation, early administration may improve outcome."

While DNP itself is considered by many to be too risky for human use, its mechanism of action remains under investigation as a potential approach for treating obesity.Currently, research is being conducted on uncoupling proteins naturally found in humans.